Data-Powered Decision-Making in Personalized Medicine: Increasing the Frequency of Patient Engagement - Diaceutics
+

Data-Powered Decision-Making in Personalized Medicine: Increasing the Frequency of Patient Engagement

July 22nd, 2013

Sanna Jousi

In this Expert Insight, Sanna Jousi of Diaceutics discusses patients’ perceptions of the pharmaceutical industry and diagnostic testing and the opportunity this presents for the pharma and the diagnostic industries to connect with patients.

A recent survey illustrated the perception of consumers towards the pharmaceutical industry. We will not go into the details again as you can read more here. However, this survey and others prompted us (wearing our personalized medicine hats, of course) to consider how companion diagnostics might change the nature of pharma/patient involvement. To do this, we set out using social media, to contrast the attitudes patients had about Zelboraf during a four-week period after its launch, versus another non-targeted oncology therapy during the same period shortly after its launch.

Both therapies carried the same positive reaction in about 14 per cent of patients, but a negative reaction was observed in 50 per cent of patients commenting on the non-targeted therapy versus only 17 per cent in patients commenting on Zelboraf. Only 36 per cent of consumers were neutral-factual in their comments about the non-targeted therapy versus 70 per cent in Zelboraf.

We surmised this was too small a sample despite the perceptual differences in targeted versus non-targeted therapies and, as a result, we do not wish to extrapolate too much from these data points at this stage. A more extensive patient engagement initiative is underway and we will report back on that in due course.

However, as we probed around different levels of consumer engagement on social media regarding health care, we did spot something most compelling. Patients talk about diagnostics and testing four times more frequently than they talk about treatment. We have repeated this analysis several times over the past 18 months and always see the same thing. Patient activity begins not with a discussion of the right therapy, but the right test. This presents an enormous opportunity for pharma and diagnostic leaders in personalized medicine to interact with patients to discuss their testing choices. We cannot guarantee it will singlehandedly reverse the negative perception consumers have of pharma, but we do conjecture that the concept of targeted therapy and targeted companion testing opens up new opportunities to change the narrative.

Blogs

View all blogs

Webinars & Podcasts

August 20th, 2019
Podcast: How Diaceutics is repairing the diagnostic testing ecoystem for patients worldwide
Diaceutics CEO, Peter Keeling joins Pat Kenny on Newstalk FM to discuss how analyzing Big Data to implement better diagnostic testing can help patients access better treatment options for cancer and other life-threatening diseases.
July 5th, 2019
Liquid Biopsy in NSCLC
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

October 21st, 2019
Pharma Precision Medicine Readiness Report 2019
March 16th, 2018
PM Readiness Report 2018 Summary
View all reports

Case Studies

View all case studies

Publications

June 25th, 2019
FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with 5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved surviv...
May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
View all publications